Nikhil Lalwani's Insider Trades & SAST Disclosures
Nikhil Lalwani's most recent trade in ANI Pharmaceuticals Inc was a trade of 17,455 Common Stock done at an average price of $64.3 . Disclosure was reported to the exchange on March 23, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Nikhil Lalwani.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 64.26 per share. | 23 Mar 2025 | 17,455 | 468,179 (3%) | 0% | 64.3 | 1,121,658 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.62 per share. | 07 Mar 2025 | 17,060 | 485,634 (4%) | 0% | 60.6 | 1,034,177 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.89 per share. | 28 Feb 2025 | 12,216 | 502,694 (4%) | 0% | 61.9 | 756,048 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 91,399 | 461,777 (3%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 60,932 | 522,709 (4%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.92 per share. | 12 Feb 2025 | 7,799 | 514,910 (4%) | 0% | 58.9 | 459,517 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.00 per share. | 26 Nov 2024 | 30,000 | 403,859 (3%) | 0% | 29 | 870,000 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 57.95 per share. | 26 Nov 2024 | 30,000 | 373,859 (3%) | 0% | 58.0 | 1,738,500 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2024 | 30,000 | 138,027 | - | - | Stock Option (right to buy) | |
| ANI Pharmaceuticals Inc | Lalwani Nikhil | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 58.30 per share. | 26 Nov 2024 | 3,481 | 370,378 (3%) | 0% | 58.3 | 202,942 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.51 per share. | 08 Sep 2024 | 3,646 | 373,859 (3%) | 0% | 60.5 | 220,619 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 66.10 per share. | 14 May 2024 | 16,669 | 377,505 (3%) | 0% | 66.1 | 1,101,821 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.58 per share. | 23 Mar 2024 | 17,455 | 394,174 (3%) | 0% | 69.6 | 1,214,519 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 65.52 per share. | 06 Mar 2024 | 28,965 | 444,981 (3%) | 0% | 65.5 | 1,897,787 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.71 per share. | 06 Mar 2024 | 17,060 | 427,921 (3%) | 0% | 66.7 | 1,138,073 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 67.13 per share. | 06 Mar 2024 | 16,292 | 411,629 (3%) | 0% | 67.1 | 1,093,682 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 67.67 per share. | 29 Feb 2024 | 10,014 | 473,946 (3%) | 0% | 67.7 | 677,647 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 80,530 | 430,274 (3%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 53,686 | 483,960 (4%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 57.75 per share. | 11 Aug 2023 | 56,666 | 353,390 (2%) | 0% | 57.8 | 3,272,462 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.00 per share. | 11 Aug 2023 | 11,616 | 365,006 (3%) | 0% | 29 | 336,864 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2023 | 11,616 | 168,027 | - | - | Stock Option (right to buy) | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 61.13 per share. | 11 Aug 2023 | 11,616 | 353,390 (2%) | 0% | 61.1 | 710,086 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.82 per share. | 23 Mar 2023 | 17,455 | 250,840 (2%) | 0% | 37.8 | 660,148 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.23 per share. | 07 Mar 2023 | 9,397 | 272,560 (2%) | 0% | 44.2 | 415,629 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.23 per share. | 07 Mar 2023 | 4,265 | 268,295 (2%) | 0% | 44.2 | 188,641 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 95,530 | 346,370 (2%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 63,686 | 410,056 (3%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.61 per share. | 08 Sep 2022 | 3,646 | 281,957 (2%) | 0% | 37.6 | 137,126 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2022 | 33,352 | 285,603 (2%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2022 | 100,055 | 252,251 (2%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Purchase of securities on an exchange or from another person at price $ 27.69 per share. | 21 Mar 2022 | 7,224 | 169,650 (1%) | 0% | 27.7 | 199,997 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.20 per share. | 08 Sep 2021 | 2,577 | 162,426 (1%) | 0% | 28.2 | 72,671 | Common Stock |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2021 | 136,495 | 165,003 (1%) | 1% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2020 | 179,643 | 179,643 | - | - | Stock Option (right to buy) | |
| ANI Pharmaceuticals Inc | Nikhil Lalwani | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2020 | 28,508 | 28,508 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges